to take a little off the table!!!! the crazy
analyist have hyped a good solid company a little to
much....agn multiple now higher than most pure plays in
pharmaceuticals(exception being the ones thought to be in play),and
remember folks this aint no pure pharm play...the
derm,contact lens solution and medical device businesses do
not deserve anything close to 40 times 1999
eps....how about 15 or 20???....in any event,agn is a great
company long term ,but it isnt worth anything close to
I'm not sure whether that describes you, but your
credibility in eyecare is questionable if you can't spell
Enough on this subject. We'll
both have to wait and see what kind of actual
performance Restatsis will have.
It's obvious that you are not an ophthalmologist.
If you were you would clearly understand the niche
market that Restasis will fit into. Oh, and by the way,
cyclosporin is not the most comfortable medication there is
While you are absolutely right about the severity
of a potential problem of dry eye, the vast majority
(those who buy otc drops now) will never in your
lifetime go blind. Yes, there is an itchy, scratchy
feeling, but even with Sjogrens (spelling?) patients, they
are not going blind in large numbers. There is
extreme discomfort. This drug will never, and can never
be justified as a drug to save eyesight.
Ophthalmologists have far greater concerns for the potential of
losing an eye like pseudomonas, than they ever will with
dry eye. This drug is clearly a niche product.
Tears lubricate and moisten the cornea - the
clear "window" to the lens. If your cornea dries out
and/or become abraded and infected you will become
blind. Dry eyes are a big deal.
Red Dwarf MD
This drug has nothing to do with losing eyesight.
It's for dry eye. Yes very uncomfortable, but not
sight threatening. The drug will probably also be used
for allergies. Not sight threatening here either.